Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin in schizophrenia cognitive impairment
NCT04846881Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- Classical Binding Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Iclepertin 10 mg with Placebo (2 arms). Primary endpoint: Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery Overall Composite T-score at 26 weeks. Started Aug 2021; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04846881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846881.